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A simple and sensitive method using solid phase microextraction (SPME) and liquid chromatography
(LC) with heated online desorption (SPME-LC) was developed and validated to analyze
anticonvulsants (AEDs) in human plasma samples. A heated lab-made interface chamber was used in
the desorption procedure, which allowed the transference of the whole extracted sample. The SPME
conditions were optimized by applying an experimental design. Important factors are discussed such as
fiber coating types, pH, extraction time and desorption conditions. The drugs were analyzed by LC,
using a C18 column (150 mm  4.6 mm  5 mm); and 50 mmol L1, pH ¼ 5.50 ammonium acetate
buffer : acetonitrile : methanol (55 : 22 : 23 v/v) as the mobile phase with a flow rate of 0.8 mL min1.
The suggested method presented precision (intra-assay and inter-assay), linearity and limit of
quantification (LOQ) all adequate for the therapeutic drug monitoring (TDM) of AEDs in plasma.
1. Introduction
Anticonvulsants (AEDs) are drugs used to control epilepsy, the
most common worldwide neurological disorder. The seizures
may cause injuries such as anxiety, embarrassment and occa-
sionally death. In the majority of cases it can be controlled using
a single antiepileptic drug, however in other cases drug poly-
therapy is essential.1 Phenobarbital (PHB), phenytoin (PHY)
and carbamazepine (CBZ) are drugs widely applied in clinical
polytherapy management of epilepsy. CBZ is metabolized
predominantly in the liver by the CYP3A4 and CYP2C8
subtypes of cytochrome P450, producing CBZ-10,11-epoxide
(CBZ-EP) and other derivatives, the first one presents the same
antiepileptic properties as CBZ.2 The polytherapy requires some
attention because the antiepileptic therapy is a chronic treatment
and may last throughout the patient’s life. Therefore, therapeutic
drug monitoring (TDM) of AEDs is fundamental to optimize
a patient’s clinical response, maximize the therapy effectiveness
while decreasing the occurrence of toxic and/or adverse effects,
common in co-medicated patients.
Several methods have been published for determination of one
or more AEDs in biological fluids for the TDM purpose. There
are several methods applying liquid chromatography (LC) with
ultraviolet detection (LC-UV),3–6 LC coupled to a single mass
spectrometer detector (LC-MS)2 and in tandem MS (LC-MS/
MS),7,8 mixed micellar LC,9 micellar electrokinetic capillary
chromatography (MEKC),10 capillary electrophoresis (CE),11
gas chromatography coupled to MS (GC-MS),12,13 and GC
coupled to thermionic detector (GC-TSD).14 The thermal insta-
bility of CBZ makes LC more attractive than GC, since for
analysis using GC a derivatization procedure is required.
Several sample preparation techniques have been used before
the chromatographic analysis. Most of these methods are labo-
rious, time-consuming and moreover, they require expensive and
toxic solvents. Among them are liquid–liquid extraction
(LLE)1,8,15–18 and solid phase extraction (SPE).12,13,19–21 Evalua-
tion of a column switching technique has been carried out for this
analysis;22 besides the fact that this technique is modern, rapid,
and consumes a small sample volume it involves complex and
expensive instrumentations.
The pressure to minimize the usage of large amounts of
solvents prompted the development of microextraction tech-
niques such as solid phase microextraction (SPME), liquid phase
microextraction (LPME), dispersive liquid–liquid micro-
extraction (DLLME), stir bar sorptive extraction (SBSE) and stir
rod sorptive extraction (SRSE). These techniques involve a non-
exhaustive transference of analytes from the sample by equilib-
rium in small portions of sorbents by either direct or indirect
contact (headspace).23
Some of these miniaturized techniques have been reported for
the determination of anticonvulsants in biological fluids by LC.
More recently, SBSE24 and DLLME25 have been used in the
TDM of the anticonvulsants and determination of CBZ in urine,
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plasma and water. SPME has been utilized in the determination
of anticonvulsants using either an off-line desorption step
followed by LC analysis or directly into a GC injector. Cantu
et al.26 used lab-made and commercial SPME fibers for the
determination of antidepressants and anticonvulsants in plasma
by LC after off-line liquid desorption. The off-line desorption
step could introduce errors and present low desorption capacity.
These limitations could be overcome with an interface chamber
that allows the desorption to be carried out by using an online set
up.27 The usage of a mild heat in the desorption step could
enhance the analyte desorption and at the same time decrease the
variation between analyses as well as the carryover effect.28
Currently, only one study has been found using desorption
online mode SPME-LC with a lab-made heated interface
chamber to determine fluoxetine in plasma.29 In this study,
a method for simultaneous determination of four anticonvul-
sants in plasma (CBZ, CBZ-EP, PHB and PHT) by SPME-LC
has been developed. Static liquid desorption was carried out with
the assistance of an online lab-made interface chamber fitted with
a temperature control unit. Three types of fiber coatings were
tested and compared: polydimethylsiloxane–divinylbenzene
(PDMS–DVB), polyacrilate (PA) and carbowax-templated resin
(CW/TPR). The method was optimized using an experimental
design thereafter validated according to ANVISA30 and FDA
guidelines.31
2. Experimental
2.1 Chemicals and reagents
Anticonvulsant analytical standards of CBZ, CBZ-EP, PHB,
PHT and hydantoin (HDT) used as internal standard (IS) were
provided by Sigma-Aldrich (Steinheim, Germany). Methanol,
acetonitrile, ammonium acetate, and potassium hydrogen
phosphate were purchased from Mallinckrodt (Paris, USA).
Potassium dihydrogen phosphate from Reagen (Rio de Janeiro,
Brazil), sodium chloride from Grupo Quımica (Rio de Janeiro,
Brazil) were also used. All reagents and solvents were of
analytical and HPLC grade. The water used to prepare the
samples and solutions was purified in aMilli-Q Ultra-PureWater
System (Millipore, Bedford, USA). Drug-free plasma was
donated by Hospital Irmandade Santa Casa de Misericordia de
Sa˜o Carlos (Sa˜o Carlos, SP, Brazil) and stored at 20 C until
used.
2.2 Instruments
The manual SPME fiber holder, CW/TPR (50 mm coating
thickness), PDMS–DVB (60 mm coating thickness) and PA
(85 mm coating thickness) SPME fibers were purchased from
Supelco (Bellefonte, PA, USA). An in-house designed interface
chamber for online coupling SPME-LC was designed and built in
our laboratory as discussed in a previous study.27
The LC system (LC-10AVP) consisted of two pumps (LC
10ATVP), an oven (CTO-10ASVP), a fixed wavelength ultravi-
olet detector (SPD-10AVVP), an autoinjector (SIL-10AF),
a system controller (SCL-10AVP), a degasser (DGU-14A) and
an acquisition software Class-VP, all from Shimadzu (Kyoto,
Japan).
2.3 Chromatographic conditions
The mobile phase consisted of ammonium acetate buffer
(50 mmol L1, pH¼ 5.50), acetonitrile and methanol (55 : 22 : 23
v/v) at a flow rate of 0.8 mL min1. The chromatographic sepa-
ration was achieved using a Shimadzu ODS column (150 
4.6 mm  5.0 mm) at 45 C, and detection at 220 nm. Injection
volumes of 20 mL and 60 mL were used for the autoinjector and
the interface chamber.
2.4 SPME procedures
SPME extractions were performed in 5 mL vials containing
triangular magnetic bars to stir the sample during the extraction.
One millilitre of spiked plasma in 4.0 mL of 60 mmol L1
phosphate buffer (pH ¼ 5.0) was used in all analyses, magnetic
stirring was performed at 1200 rpm. After the extraction, the
SPME fiber was inserted directly in the in-house interface
chamber and the desorption step was performed at 60 C during
20 min in the static mode. New fibers were conditioned in the
mobile phase, the same procedure was carried out after each
analysis cleaning the SPME fibers in acetonitrile and methanol
(7 : 3) to avoid carry-over effect.
Eleven experiments were performed to optimize the SPME
extraction step using a fractional experimental design (241) with
the central point in triplicate. Relevant parameters such as
extraction time (10 and 45 min), extraction temperature (30 and
60 C), pH (5 and 10) and ionic strength (0 and 30%m/v of NaCl)
were evaluated. The model obtained was evaluated using
ANOVA, Pareto charts and response surface using Statistica 6.0.
Different desorption temperatures (40, 50 and 60 C) were
studied to evaluate their effect in the SPME extraction.
2.5 Preparation of analytical standards
Stock solutions of CBZ, CBZ-EP, PHB, PHT and HDT were
prepared in methanol at a concentration of 1000 mg L1 and
maintained at 4 C for 1 week. Working solutions were prepared
at 75 and 375 mg L1 for CBZ, CBZ-EP and HDT, and 200 and
1000 mg L1 for PHB and PHT by diluting the stock solutions on
the day of use.
Human plasma was centrifuged (7100g  15 min) and filtered
through 0.22 mmmembranes. In order to reach concentrations of
1.50, 3.25, 7.25, 11.25, 15.0 and 18.75 mg L1 of CBZ and CBZ-
EP and 4.0, 10.0, 20.0, 30.0, 40.0 and 50.0 mg L1 of PHB and
PHT, suitable aliquots of working solutions were added to 5 mL
vials and dried under nitrogen. Subsequently, they were sus-
pended in 1.0 mL of drug-free plasma and 4.0 mL of 60 mmol L1
phosphate buffer.
2.6 Validation procedure
Method specificity was evaluated using five blank plasma
samples, one of those was from hemolyzed blood. The presence
of interferents with the same retention time as CBZ, CBZ-EP,
PHB, PHT and HDT was evaluated.
Linearity was determined by analysis of spiked blank plasma
samples in six concentration levels in five replicates: 1.50, 3.25,
7.25, 11.25, 15.0 and 18.75 mg L1 of CBZ and CBZ-EP; 4.0,
10.0, 20.0, 30.0, 40.0 and 50.0 mg L1 of PHB and PHT. HDT, as
1520 | Anal. Methods, 2012, 4, 1519–1524 This journal is ª The Royal Society of Chemistry 2012
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internal standard (IS), was maintained at a concentration of
30 mg L1. The linearity was estimated based on the regression
curves (y ¼ ax + b) and coefficient of determination (r2).
The intra-assay precision was estimated in three levels in
triplicate (low, medium and high). The inter-assay was deter-
mined using the same concentration levels in triplicate, but in two
different days. The precision was expressed as relative standard
deviations (%RSD).
The recovery was estimated by comparing direct injection of
60 mL of analytical standards, the same volume of interface, to
spiked plasma samples in the same mass levels of the direct
injection.
The limit of detection (LOD) was the lowest concentration at
which the response was higher than three times the average of the
baseline noise. The limit of quantification (LOQ) was the lowest
concentration level required to quantify the compounds based on
the therapeutic concentration level of each compound with
precisions lower than 20% obtained in three replicates.
3. Results and discussion
3.1 Chromatographic conditions
Fig. 1 presents a representative chromatogram of a spiked blank
plasma. As can be observed in this figure, the peaks are sharp and
well resolved for all compounds tested at pH 5.5 without peak
tailing. The mobile phase was chosen based on good separation
and short analysis time (10 min). Other mobile phase composi-
tions were tested containing water : acetonitrile (70 : 30),
100 mmol L1 acetate buffer : acetonitrile : methanol
(64 : 19 : 17) at pH 6.5 and 7.5, however they did not present
adequate resolution and separation.
3.2 SPME optimization
The first procedure consisted of selecting the SPME fiber coating
appropriate to extract the analytes. In Fig. 2 it is observed that
the PDMS–DVB fiber coating presented enough chemical
affinity to extract all the analytes. The CW/TPR fiber coating
showed a similar performance in comparison to the PDMS–DVB
fiber coating, however the latter one was chosen because it was
more resistant than the CW/TPR type. At least 22 extractions
were performed with PDMS–DVB fiber coating without
compromising the analytical response, while for CW/TPR fiber
coating with less than 22 extractions macroscopic damages on
the fiber surface appeared, resulting in reduction of the analyte’s
signal. PDMS-DVB fiber has suitable properties for analyzing
polar amines; particularly in this analysis, anticonvulsants
present amine groups combined with aromatic rings in their
structures suitable to be extracted by this polymeric coating.
The experimental design allowed the SPME optimization with
low reagent consumption. Eleven analyses were sufficient to
achieve the optimum extraction procedure. ANOVA was used to
evaluate the parameters with 95% confidence interval. The model
presented the coefficient of determination r2 ¼ 0.9821 and
adjustment of 0.9404, thus suggesting that this model fits
accordingly.
The extraction temperature had a negative non-significant
effect (p > 0.05). Indeed, this temperature is expected to present
a dual behavior regarding partition equilibrium and diffusion.
Increasing the temperature increases the analyte diffusion to the
fibers. In contrast, the partition coefficient from the sample to the
extraction phase is decreased with increasing extraction
temperature. Here the latter factor prevailed, reducing signifi-
cantly the SPME efficiency. Despite that, temperature was a non-
significant parameter, which allowed the use of low temperature
values during the extraction procedure. Time behaved in a posi-
tive significant way (p < 0.05), increasing the extracted amount.
SPME extraction is based on partition between phases; therefore
it required a certain amount of time to reach equilibrium, which
depends on the analyte, matrix and fiber coating. In this method,
45 min was necessary to achieve equilibrium and obtain the
maximum extraction yield.
The ionic strength was evaluated by adding salt, being inves-
tigated as 0 and 30% (m/v) of NaCl. This parameter presented
a positive significant effect (p < 0.05) in the extraction that could
be explained by the salting out effect. The salt solvates the
molecules of water present in the matrix allowing the free ana-
lytes to interact directly with the fiber coating. Addition of 30%
(m/v) of NaCl was demonstrated to be the best condition to
Fig. 1 Chromatogram of SPME extraction of 50 mg L1 of PHB (1) and
PHT (3), 18.75 mg L1 of CBZ-EP (2) and CBZ (4), and 30 mg L1 of IS
(5) in plasma using the lab-made interface.
Fig. 2 SPME extraction performance for different types of coating
films.
This journal is ª The Royal Society of Chemistry 2012 Anal. Methods, 2012, 4, 1519–1524 | 1521
D
ow
nl
oa
de
d 
by
 U
N
IV
ER
SI
D
A
D
 S
A
O
 P
A
U
LO
 o
n 
10
/0
4/
20
13
 1
8:
54
:5
3.
 
Pu
bl
ish
ed
 o
n 
17
 A
pr
il 
20
12
 o
n 
ht
tp
://
pu
bs
.rs
c.
or
g 
| do
i:1
0.1
039
/C2
AY
250
47K
View Article Online
enhance the SPME extraction ratio. pH was the parameter that
exhibited the highest influence on the extraction of the most
critical analytes, with a negative effect (p < 0.05), therefore pH
5.0 was selected. The anticonvulsants have pKa varying from 7.30
to 13.0; PHB and PHT are weak acids and at pH ¼ 5.0 they are
expected to be in the non-ionized form. CBZ and CBZ-EP have
a pKa ¼ 13.4, thus at pH ¼ 5.0 both compounds are expected to
be in the ionized form. At pH 10.0 PHB and PHT are expected to
be ionized, hindering their absorption into the PDMS–DVB fiber
coating. In such a situation, adsorption would be the main
mechanism of extraction, explaining a lower response in
comparison when both mechanisms act in synergy. On the other
hand, at pH 5.0 both adsorption and absorption processes occur
simultaneously and consequently they contribute to increase the
extraction ratio. However, even in the ionized form, CBZ and
CBZ-EP showed higher signal response than PHB and PHT.
Therefore, in order to maximize the extraction of the analytes
with lower responses, SPME conditions were selected according
to the model that enhanced the detectability of PHB and PHT.
After all, the optimized extraction conditions were: extraction
temperature at 30 C during 45 min, 30% (m/v) of NaCl and pH
5.0. Fig. 3 presents these effects evaluated during the experi-
mental design, without statistically significant interactions
among the parameters.
The interface chamber allowed an on-line desorption proce-
dure improving the analyte desorption compared to an off-line
procedure. Moreover, the interface chamber allowed the injec-
tion of the whole amount desorbed in contrast with the off-line
procedure, in which only part of the solution is injected. Fig. 4
presents the improvement of analyte desorption when the inter-
face was heated. The equilibrium of the partition fiber/mobile
phase decreases with increasing temperature and consequently it
improves the desorption process. The desorption temperature of
60 C improved the peak areas for CBZ, CBZ-EP and PHT, with
an exception for PHB. By observing the chromatogram obtained
using desorption at 60 C, one can note some small low retained
peaks, which may indicate that a partial degradation of PHB is
not completely disregarded. However, the method precision,
selectivity and sensitivity were not compromised in the whole
concentration range for PHB. A final temperature of 60 C was
then selected because at higher temperatures the solvent could
evaporate changing the peak area obtained (81 C, acetonitrile’s
boiling point). Moreover, all the analytes demonstrated suitable
desorption at 60 C, without a carryover effect.
3.3 Method validation
Table 1 shows the validation parameters that defined the analysis
of anticonvulsants in plasma.
3.3.1 Specificity. No peak eluted in the same retention time
of any of the evaluated analytes. Fig. 4 presents a chromatogram
of a spiked blank plasma sample obtained after SPME extraction
and desorption using the lab-made interface chamber.
3.3.2 Linearity and precision. The method studied demon-
strated linearity suitable for TDM analysis of anticonvulsants in
plasma with a linear regression coefficient higher than 0.992 for
all drugs tested. The RSD in the intra-assay evaluated in all
concentrations was lower than 11.52. The inter-assay presented
an RSD below 20% for all compounds (data not shown).
3.3.3 Limit of detection (LOD) and quantification (LOQ).
The LOD was established as the concentration where the
compound peak signal was three times superior to the baseline
noise. LOD values determined were 0.015 mg L1 for CBZ,
0.030 mg L1 for CBZ-EP, and 0.040 mg L1 for PHB and PHT.
The LOQ was defined according to the therapeutic range of each
drug with precision lower than 20%. LOQ values obtained were
1.5 mg L1 for CBZ and CBZ-EP, and 4.0 mg L1 for PHB and
PHT.
The method proposed presented a LOD lower than those of
other methods reported previously using traditional sample
preparation techniques such as LLE and SPE which are
exhaustive extraction techniques.5,6
Queiroz et al.24 report the use of SBSE with off-line desorption
for the analysis of this class of drugs. In spite of the SBSE bar
being coated with a thicker film than that used in this study, their
method presented a lower LOD due to the off-line desorption
and showed lower performance. Due to the off-line desorption,
the same issue was observed in the method reported by Cantu
et al.26 using SPME with off-line desorption to determine anti-
convulsants and antidepressants in plasma. Our study showed
that controlled temperature in the desorption procedure is
Fig. 3 Pareto chart of anticonvulsants obtained by a fractionary
experimental design.
Fig. 4 Effect of the desorption temperature after extraction using
SPME: (1) PHB, (2) CBZ-EP, (3) PHT and 4 (CBZ). Different desorption
temperatures tested are 40 C (blue line), 50 C (black line) and 60 C (red
line).
1522 | Anal. Methods, 2012, 4, 1519–1524 This journal is ª The Royal Society of Chemistry 2012
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fundamental to completely desorb the compounds, and essential
to improve the response at low concentrations. Fernandes et al.29
used a similar lab-made interface chamber with controlled
temperature obtaining an LOD similar to that by the method
being studied. Table 2 shows a summary of different methods
used for the analysis of the same compounds and their
comparison to the proposed method.
3.3.4 Recovery. Table 3 shows the recovery data obtained for
the same class of compounds described in the proposed study.
SPME extraction in complex matrices, such as biological fluids,
usually presents low recovery rates.32 However, these values are
common in SPME extractions because of their minimized sample
preparation technique based on equilibrium and non-exhaustive
extraction. The SPME extraction using mixed phases such as
PDMS–DVB involves both partition sorption and adsorption.
The competitive adsorption is common in simultaneous analysis
which decreases the extraction efficiency and causes low recovery
rates. Fernandes et al.29 used the same interface and reported
recovery rates from 1.94 to 10.54%, higher than those of our
method. However, only fluoxetine and norfluoxetine were
determined in plasma samples, using clomipramine as IS.
4. Conclusions
The proposed chromatographic method using the SPME-LC
interface approach has shown precision, linearity and limit of
quantification suitable for TDM of selected anticonvulsants in
plasma. The interface chamber allowed an online static desorp-
tion. Its use with the heated interface improved the desorption
process, increasing the peak area (about three-fold, except to
phenobarbital), reducing the inter-day and intra-day variation
and carry-over effect which are common in off-line desorption.
Furthermore, the experimental design contributed to optimize
the method quickly without consuming large amounts of
solvents and time.
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